Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Historically, patients with kidney diseases caused by genetic or acquired dysregulation of the complement alternative pathway have been grouped into clinical syndromes, C3 glomerulopathy (C3GN/DDD) and thrombotic microangiopathy (TMA), specifically atypical haemolytic uremic syndrome (aHUS). Recent data suggested that these diseases share a common pathophysiology and that patients can transition between glomerulopathies in this spectrum.
Please note, in the section entitled “Combination of radium-223 and docetaxel is well-tolerated, and improves time to prostate-specific antigen progression and progression-free survival in men with metastatic CRPC” on page S144 of the recently published “Prostate cancer update from the American Society of Clinical Oncology (ASCO) Annual Meeting 2016” supplement (see below), the incorrect drug combination was stated. CUAJ regrets the error and apologizes for any inconvenience.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
